MOTS-c: The Mitochondrial Metabolic Peptide

MOTS-c is a 16-amino acid peptide discovered in 2015 by researchers at the University of Southern California. It's encoded by the mitochondrial genome (mtDNA) rather than nuclear DNA, making it part of a new class called "mitochondrial-derived peptides" (MDPs).

Key functions:

• Regulates glucose and fatty acid metabolism
• Improves insulin sensitivity and glucose uptake
• Enhances mitochondrial function and biogenesis
• Activates AMPK (master metabolic regulator)
• Protects against age-related metabolic decline
• Improves exercise capacity and endurance

MOTS-c acts as a "mitokine" — a signaling molecule from mitochondria that communicates cellular energy status to the nucleus and regulates metabolic adaptation.

1. Insulin Sensitivity & Glucose Regulation

• MOTS-c improves insulin sensitivity in skeletal muscle and adipose tissue
• Increases glucose uptake without requiring insulin (insulin-independent pathway)
• Reverses insulin resistance in diet-induced obesity models
• May have therapeutic potential for type 2 diabetes

2. Fat Metabolism & Weight Management

• Enhances fatty acid oxidation (fat burning)
• Prevents diet-induced obesity in animal models
• Reduces visceral fat accumulation
• Improves metabolic flexibility (ability to switch between fuel sources)

3. Mitochondrial Function

• Increases mitochondrial biogenesis (creation of new mitochondria)
• Improves mitochondrial respiration and ATP production
• Protects mitochondria from age-related dysfunction

4. Exercise Performance

• Improves endurance and exercise capacity in animal studies
• Enhances muscle glucose uptake during exercise
• May improve recovery and adaptation to training

5. Longevity & Aging

• MOTS-c levels decline with age
• Supplementation reverses age-related metabolic decline in mice
• May extend healthspan through metabolic optimization

Key studies on MOTS-c:

• Discovery study (Lee et al., 2015): Identified MOTS-c and demonstrated its metabolic regulatory effects in mice and cells
• Insulin resistance reversal (Lee et al., 2015): MOTS-c treatment reversed diet-induced insulin resistance and obesity in mice
• Exercise capacity (Reynolds et al., 2021): MOTS-c improved running capacity and muscle function in aged mice
• Human genetic variants (Fuku et al., 2015): Specific MOTS-c genetic variants associated with longevity in Japanese centenarians

Current limitations: Most MOTS-c research is preclinical (animal and cell studies). Human clinical trials are limited but ongoing. Optimal dosing for humans is still being established.

MOTS-c dosing is still being optimized. Current research protocols:

Metabolic Health & Fat Loss:

• Dose: 5-15 mg per injection
• Frequency: 2-3 times weekly (Monday/Wednesday/Friday)
• Route: Subcutaneous or intramuscular
• Duration: 4-8 weeks, then reassess

Athletic Performance & Training Support:

• Dose: 10-20 mg per injection
• Frequency: 2-3 times weekly
• Timing: Post-workout or on training days preferred

Anti-Aging & Longevity:

• Dose: 5-10 mg per injection
• Frequency: 2 times weekly
• Duration: Cycled (8-12 weeks on, 4 weeks off)

Some researchers use daily micro-dosing (2-5 mg daily), while others prefer larger doses less frequently. Response appears highly individual.

Week 1-2:

• Improved energy and endurance during exercise
• Better workout recovery
• Slight improvements in blood glucose stability (if monitoring)

Week 2-6:

• Noticeable improvements in body composition (fat loss, muscle preservation)
• Enhanced metabolic flexibility (less energy crashes between meals)
• Improved insulin sensitivity (measurable via fasting glucose/insulin)

Week 6-12:

• Sustained metabolic improvements
• Continued fat loss with preserved lean mass
• Potentially improved mitochondrial markers (requires specialized testing)

Results are most dramatic in individuals with metabolic dysfunction (insulin resistance, obesity, sedentary lifestyle). Athletes and metabolically healthy individuals may notice more subtle benefits.

MOTS-c is gaining attention in athletic communities for its exercise-mimetic and performance-enhancing properties:

• Endurance: Improves aerobic capacity and time to exhaustion in animal studies
• Recovery: Enhances muscle glucose uptake and glycogen replenishment post-exercise
• Adaptation: May amplify training adaptations through AMPK activation
• Body composition: Supports fat loss while preserving lean muscle mass

Many researchers use MOTS-c during cutting phases or endurance training blocks for its metabolic benefits.

MOTS-c is supplied as lyophilized powder:

• Reconstitution: Use bacteriostatic water. For a 10 mg vial, add 1-2 mL = 5-10 mg/mL
• Storage: Reconstituted peptide stable 2-4 weeks refrigerated. Lyophilized powder stable months to years frozen.
• Injection: SC (abdomen, thigh) or IM (glute, deltoid) using insulin or regular syringes
• Timing: Post-workout or morning fasted are common preferences

MOTS-c stacks synergistically with metabolic and longevity peptides:

• + NAD+: Complementary mitochondrial optimization and energy metabolism
• + Epithalon: Combined metabolic + longevity signaling
• + Semaglutide/Tirzepatide: Enhanced insulin sensitivity + appetite suppression for fat loss
• + CJC-1295/Ipamorelin: Improved body composition through complementary pathways

MOTS-c appears well-tolerated based on limited human data and extensive animal research:

• Minimal reported side effects in current protocols
• Occasional: Mild injection site reactions, temporary fatigue
• No serious adverse events documented

As a relatively new peptide (discovered 2015), long-term human safety data is limited. Conservative dosing and cycling are prudent.

Ascension Peptides is our recommended source for research-grade MOTS-c:

• Third-party tested with ≥98% HPLC purity
• Published Certificates of Analysis
• Proper 16-amino acid sequence verification
• US-based with reliable cold-chain shipping

MOTS-c is a short peptide but must be synthesized correctly for activity. Always verify third-party testing.